// App-Quantinova.ai

3677 : MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study

Researchers

Presenter

  • Mehdi Hamadani

Principal Investigators

  • Jaime Perez de Oteyza

  • Jose Francisco Tomas

  • Antonio Cuneo

  • Weiya Zhang

  • Trishna Goswami

  • Ramy Ibrahim

  • Zhenling Yao

  • Ronald Herbst

  • Bruce D. Cheson

  • Celeste M. Bello

  • Thomas J Kipps

  • Fritz Offner

  • Gregor Verhoef

  • Massimo Federico

  • Stephanie A. Gregory

  • Anne Sonet

  • Sarit Assouline

Medical Centers

  • Department of Hematology, University Hospital Leuven, Leuven, Belgium

  • Department of Hematology, University of Ferrara, Ferrara, Italy

  • Hematology/Oncology Bone Marrow Transplant, West Virginia University Hospitals, Inc., Morgantown, WV, USA,

  • Hematology-BMT Unit, MD Anderson Spain, Madrid, Spain

  • Dienst Hematologie, UZ Ghent, Gent, Belgium

  • Division of Hematology and Department of Oncology, Jewish General Hospital, Montreal, QC, Canada

  • Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy

  • Servicio de Onco-Hematologia, Hospital Madrid Norte-Sanchinarro, Madrid, Spain

  • Cliniques Universitaires UCL Mont-Godinne - Pharmacie, Yvoir, Belgium

Locations

  • Canada

  • Italy

  • Spain

  • United States

  • Belgium

Companies

  • MedImmune Inc. (Astr

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Chronic Lymphocytic Leukemia

  • B cell lymphomas

  • Follicular lymphoma

  • Multiple Myeloma

  • Neutropenia

  • Lymphomas

  • Sepsis

Biomarkers

  • Immunoglobulin G

Drug/Treatment

  • MEDI 551

Outcome

  • N/A

Study Design

  • open label

  • pharmacokinetics

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved